Trial Profile
A study evaluating predictive value of PD-L1 for the response to ipilimumab in the treatment of stage IV melanoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2017
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 11 Dec 2017 New trial record